Page 48 - Nsclc News Today

About 1 in 4 patients with non–small cell lung cancer have an unsatisfactory antibody response to the Omicron variant following COVID-19 vaccination, reports a new study.

An analysis of lung cancer screening since March 2021, when eligibility criteria were expanded, shows that significantly more Black men have been screened, but not women or undereducated people.

Which is better? Concurrent neoadjuvant chemotherapy and immunotherapy or concurrent adjuvant chemotherapy with immunotherapy for non–small cell lung cancer (NSCLC)?

The KRAS (G12C) inhibitor adagrasib induced an objective response in about one out of three patients with previously treated KRAS (G12C)–mutated non–small cell lung cancer (NSCLC).

Long thought to be untreatable, KRAS-mutant cancers are now the target of two new drugs.

The tyrosine kinase inhibitor has already been approved for certain patients with non-small cell lung cancer and anaplastic large cell lymphoma.

Proprietary microRNA signature (miRisk) may support immunotherapy treatment decisions as a blood-based complementary diagnostic Results published in Journal of Thoracic Oncology Clinical and Research

The drug combination, which received accelerated approval from the FDA for patients aged 6 years and older, is the only BRAF/MEK inhibitor okayed for use in pediatric patients.

Patients with urothelial carcinoma demonstrated improved overall survival as well. The study was published as a preprint and has not yet been peer reviewed.

Three cycles of neoadjuvant nivolumab plus chemotherapy improved long-term clinical outcomes in patients with resectable stage IB-IIIA NSCLC.